公开(公告)号：US20240309016A1

公开(公告)日：2024-09-19

申请号：US18606857

申请日：2024-03-15

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Mitsunori KONO ,  Yusuke SASAKI ,  Yuya OGURO ,  Zenichi IKEDA ,  Osamu KUBO ,  Masaki SETO ,  Toru YAMASHITA ,  Makoto KAMATA ,  Kenjiro SATO ,  Matthew Thomas REYNOLDS ,  Kazuaki TAKAMI ,  Asato KINA ,  Takafumi YUKAWA ,  Minoru NAKAMURA ,  Taku KAMEI ,  Hiroyuki KAKEI ,  Fumie YAMAGUCHI ,  Tomohiro OHASHI ,  Keiko KAKEGAWA ,  Takuto KOJIMA ,  Florian PÜNNER ,  Masataka MURAKAMI ,  Takahiko TANIGUCHI ,  Tatsuki KOIKE ,  Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Yasushi HATTORI ,  Eiji KIMURA ,  Martin Alexander PAWLICZEK ,  Marilena PIRA ,  Shuhei IKEDA ,  Noriyuki TEZUKA ,  Yoshikazu WATANABE ,  Kevin CURRAN ,  Nicolle DOERING ,  Maria HOPKINS ,  Ben JOHNSON ,  Andre KIRYANOV ,  Jon LAM ,  Sean MURPHY ,  Natasha O'ROURKE ,  Holly REICHARD ,  Paul TANIS ,  Yunlong ZHANG

IPC: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

CPC classification number: C07D498/14 ,  A61K31/407 ,  A61K31/437 ,  A61P25/26 ,  C07D498/04

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20220017514A1

公开(公告)日：2022-01-20

申请号：US17413473

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC: C07D471/04 ,  C07D231/56 ,  C07D277/64 ,  C07D215/38 ,  C07D401/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20200207734A1

公开(公告)日：2020-07-02

申请号：US16633960

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA ,  Satoshi MIKAMI ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Masaki DAINI ,  Norio OYABU ,  Masaki OGINO ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D401/06 ,  C07D211/56 ,  C07D401/10 ,  C07D405/10 ,  C07D207/14 ,  C07D417/06 ,  C07D405/12 ,  C07D409/10 ,  C07D413/06 ,  C07D401/14 ,  C07D205/04 ,  A61P25/26

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230063805A1

公开(公告)日：2023-03-02

申请号：US17846830

申请日：2022-06-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuichi KAJITA ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D211/56 ,  C07D211/36 ,  C07D405/06 ,  A61P25/26 ,  C07D409/10 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230042358A1

公开(公告)日：2023-02-09

申请号：US17413469

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Norihito TOKUNAGA ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Dilhumar UYGHUR ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO ,  Koichiro FUKUDA ,  Yasuhisa KOHARA ,  Rei OKAMOTO ,  Taiichi OHRA ,  Naoki MIYAMOTO ,  Jun CHIBA ,  Yoshito TERAO ,  Masanori KAWASAKI

IPC: C07D455/02 ,  A61P25/26 ,  C07D471/04 ,  C07D217/24 ,  C07D239/90 ,  C07D237/32 ,  C07D401/10 ,  C07D403/10 ,  C07D498/04 ,  C07D417/06 ,  C07D401/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20190040010A1

公开(公告)日：2019-02-07

申请号：US16052967

申请日：2018-08-02

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Satoshi MIKAMI ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Masaki DAINI ,  Norio OHYABU ,  Masaki OGINO ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D211/56 ,  C07D401/10 ,  C07D401/06 ,  C07D207/14 ,  C07D405/10 ,  C07D417/06 ,  C07D405/12 ,  C07D413/06 ,  C07D401/14 ,  C07D205/04 ,  C07D403/06 ,  C07D417/14 ,  A61P25/00

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20230040770A1

公开(公告)日：2023-02-09

申请号：US17427490

申请日：2020-01-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yasushi HATTORI ,  Yuhei MIYANOHANA ,  Tatsuki KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Norihito TOKUNAGA ,  Alexander Martin PAWLICZEK ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO

IPC: C07D403/06 ,  C07D207/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20210276949A1

公开(公告)日：2021-09-09

申请号：US17239191

申请日：2021-04-23

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yasushi HATTORI ,  Yuhei MIYANOHANA ,  Yuichi KAJITA ,  Tatsuki KOIKE ,  Yasutaka HOASHI ,  Norihito TOKUNAGA ,  Alexander Martin PAWLICZEK ,  Tsuneo ODA ,  Tohru MIYAZAKI ,  Yoshiteru ITO ,  Kohei TAKEUCHI ,  Keisuke IMAMURA ,  Takahiro SUGIMOTO

IPC: C07D207/14 ,  C07D407/08 ,  C07D417/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20200207715A1

公开(公告)日：2020-07-02

申请号：US16811426

申请日：2020-03-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D211/56 ,  C07D417/14 ,  C07D417/06 ,  C07D413/06 ,  C07D405/12 ,  C07D405/10 ,  C07D403/06 ,  C07D401/14 ,  C07D401/10 ,  C07D401/06 ,  C07D207/14 ,  C07D205/04 ,  A61P25/00 ,  C07D405/06 ,  C07D211/36

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US20200017444A1

公开(公告)日：2020-01-16

申请号：US16577449

申请日：2019-09-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi KAJITA ,  Satoshi MIKAMI ,  Yuhei MIYANOHANA ,  Tatsuki KOIKE ,  Masaki DAINI ,  Norio OYABU ,  Masaki OGINO ,  Kohei TAKEUCHI ,  Yoshiteru ITO ,  Norihito TOKUNAGA ,  Takahiro SUGIMOTO ,  Tohru MIYAZAKI ,  Tsuneo ODA ,  Yasutaka HOASHI ,  Yasushi HATTORI ,  Keisuke IMAMURA

IPC: C07D211/56 ,  A61P25/00 ,  C07D205/04 ,  C07D207/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/06 ,  C07D405/10 ,  C07D405/12 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14 ,  C07D211/36 ,  C07D405/06

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.